#1 Clinical Trials Search in Europe

Study of GBS-NN/NN2 vaccine to prevent Group B streptococcus infection in healthy pregnant women: evaluating long-term immunity and booster dose safety during subsequent pregnancy

4 1 1

What is this study about?

This clinical trial focuses on a vaccine designed to prevent Group B Streptococcus infection. The study examines a vaccine called GBS-NN/NN2, which is given as an injection into the muscle. The purpose is to evaluate how long the immune response lasts after vaccination in pregnant women and to assess the safety and effectiveness of giving an additional booster dose during a subsequent pregnancy.

The vaccine is administered as a solution for injection, with a maximum single dose of 50 micrograms. The study will track how the body maintains protective antibodies over time after the initial vaccination. For some participants who become pregnant again during the study period, a booster dose of the vaccine will be given to examine its effects.

The study will monitor both mothers and their newborns to understand how the vaccine’s protection is passed from mother to baby. Researchers will collect blood samples from mothers at various points during pregnancy and after delivery, as well as from the umbilical cord and infants after birth. The study will also track the general health and development of both mothers and babies to ensure the vaccine’s safety.

1 Initial participation

You will be enrolled in the trial as a follow-up participant if you previously received at least one dose of GBS-NN/NN2 vaccine in Trial MVX0004 or MVX0005.

The trial focuses on monitoring the immune response to the vaccine that helps prevent Group B Streptococcus infection.

2 Annual blood tests

Your blood will be tested once a year to measure the levels of specific antibodies (IgG) against the vaccine components.

These tests will continue throughout the trial period until 2029.

3 Pregnancy monitoring – without booster

If you become pregnant during the trial period and do not receive a booster dose:

Blood samples will be collected at delivery to measure antibody levels.

A cord blood sample will be collected from your baby at birth to measure antibody levels.

4 Pregnancy monitoring – with booster

If you become pregnant and receive a booster dose of the vaccine:

Blood samples will be collected before vaccination, one month after vaccination, at delivery, and 6 months after delivery.

You will need to report any injection site reactions or general health changes for 7 days after vaccination.

Any unexpected health events will be monitored for 28 days after vaccination.

Health monitoring will continue up to 6 months after delivery.

5 Infant monitoring – with maternal booster

If you received the booster dose, your infant will be monitored as follows:

Cord blood collection at birth

Blood samples at 1 month and 3 months of age

Health checks including weight, length, and head measurements at birth

Development checkup at 6 months of age

Health monitoring will continue up to 6 months of age

Who Can Join the Study?

  • Must be a previous participant of Trial MVX0004 or MVX0005 and have received at least 1 dose of the GBS-NN/NN2 vaccine (a vaccine against Group B streptococcus infection)
  • Must be able to read, understand, and sign an informed consent (a document explaining the study details and patient rights)
  • Must be willing and able to attend all scheduled clinic visits and follow the study procedures
  • Must agree to give access to medical records related to the study and materials from previous trials MVX0004 or MVX0005
  • Must be available throughout the entire duration of the study and be reachable by phone
  • Must be female (male participants are not eligible for this study)
  • Must be of adult age (18 years or older)

Who Cannot Join the Study?

  • Female participants who are pregnant or breastfeeding
  • History of severe allergic reactions to vaccines or vaccine components
  • Active infection or fever (temperature above 38°C/100.4°F) at the time of vaccination
  • Participants who received any other vaccine within 30 days before the study
  • History of Group B streptococcus (a type of bacteria) infection
  • Current participation in another clinical trial
  • Any serious chronic medical condition that could interfere with the study
  • Use of medications that affect the immune system
  • History of serious adverse reactions to previous vaccinations
  • Individuals who are not able to comply with the study schedule
  • Blood disorders or conditions that increase risk of bleeding
  • Any condition that, in the opinion of the study doctor, makes participation unsafe

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Region Midtjylland Aarhus Denmark
Syddansk Universitet (University of Southern Denmark) Odense Denmark
Havintvk Hpceguhu Hvidovre Denmark

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Denmark Denmark
Not recruiting
07.01.2025

Trial locations

GBS-NN/NN2 is a vaccine designed to protect against Group B Streptococcus (GBS) infection. It is being studied in pregnant women to understand how long the immune protection lasts after vaccination and how well it works when given as a booster shot during subsequent pregnancies. This vaccine aims to create antibodies that can help protect both the mother and baby from GBS infection.

Group B Streptococcal (GBS) Infection – A bacterial infection caused by Streptococcus agalactiae that can affect people of all ages but primarily impacts newborns during or shortly after birth. The bacteria can naturally live in the digestive and lower reproductive tracts without causing symptoms in adults. In newborns, the infection can develop in the first week of life (early-onset) or between one week and three months of age (late-onset). The bacteria can cause various types of infections including bloodstream infections, pneumonia, and meningitis. The infection can spread from mother to baby during pregnancy or during labor and delivery.

Trial ID:
2024-516364-28-00
Protocol code:
MVX008
Trial Phase:
Therapeutic use (Phase IV)

Other Trials to Consider

  • Study on the Safety and Immune Response of GBS-NN/NN2 and Tdap Vaccines in Preventing Group B Strep Infection in Healthy Women Aged 18-49

    Not yet recruiting

    4 1 1
    Investigated drugs:
    Belgium Poland